Oral NKTR-181 Scientific and Clinical Data Presentations

• Poster: American Academy of Pain Medicine 28th Annual Meeting: Pain Medicine — February 2012 —NKTR-181: An Orally Available Mu-Opioid Agonist with Slow Rate of Uptake into the CNS, Exhibits Comparable Analgesic Efficacy with Reduced Abuse Liability and CNS Mediated Side Effects Compared to Oxycodone

• Poster: American Academy of Pain Medicine 28th Annual Meeting: Pain Medicine — February 2012 — Multiple Dose Pharmacokinetics and Pharmacodynamics of the New Oral Opioid Analgesic NKTR-181

• Poster: American Academy of Pain Management 22nd Annual Meeting — September 2011 — Pharmacokinetics and Pharmacodynamics of Oral NKTR-181, a Novel Opioid Analgesic: Results of a Single Ascending Dose Phase 1 Study

• Poster: American Academy of Pain Management 22nd Annual Meeting — September 2011 — NKTR-181: A Novel Opioid Analgesic That Exhibits Reduced Abuse Potential and Maintains Full Analgesic Activity Following Repeat Dosing in Preclinical Rodent Models

• Poster: Society for Toxicology 50th Annual Meeting & ToxExpo — March 2011 — NKTR-181, a Novel Polymer Conjugated Opioid Agonist, Demonstrates Reduced Toxicity and CNS Side Effects Relative to Oxycodone

• Poster: Society for Neuroscience 40th Annual Meeting — November 2010 — NKTR-181: A novel opioid analgesic with slowed CNS entry shows reduced abuse liability and CNS side effects"

• Poster: Society for Neuroscience 40th Annual Meeting — November 2010 — "Controlling the rate of entry to the CNS by polymer conjugation"

• Abstract #A509:American Society of Anesthesiologists (ASA) Annual Meeting - Anesthesiology 2010 — October 2010 — "NKTR-181, a Novel Opioid Analgesic with Slow Entry into CNS and Markedly Reduced CNS Side Effects"

• Poster: 5th Annual Frontiers of Clinical Investigation Symposium - Pain 2010: From Bench to Bedside — October 2010 — "NKTR-181: A Novel Opioid With Slowed Brain Entry Shows Low Abuse Liability and Reduced CNS Side Effects"
  Oral Abstract Presentation